Changes in NCCN Guideline
Explanation on how until recently the only available treatment in the first-line setting for metastatic castrate-resistant prostate cancer was docetaxel. Options expanded to include abiraterone and en...
Author: onclivetv
Added: 03/25/2015 (Source: Oncology Tube)
Source: Oncology Tube - March 25, 2015 Category: Cancer & Oncology Source Type: podcasts
SABCS 2014: ECOG 1199 Trial Commentary by Dr. Sunil Verma
: Ten year update of E1199: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly i...
Author: oncologyeducation
Added: 12/11/2014 (Source: Oncology Tube)
Source: Oncology Tube - December 12, 2014 Category: Cancer & Oncology Source Type: podcasts
SABCS 2014: TNT Trial Commentary by Dr. Sunil Verma
: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negat...
Author: oncologyeducation
Added: 12/11/2014 (Source: Oncology Tube)
Source: Oncology Tube - December 11, 2014 Category: Cancer & Oncology Source Type: podcasts
GALAXY1 trial - Dr. Parneet Cheema
For more updates visit www.oncologyeducation.com....
Video update from the 15th World Conference on Lung Cancer. GALAXY1 trial: Randomized Phase 2 study of docetaxel with or without ganetespib in adva...
Author: oncologyeducation
Added: 11/05/2013 (Source: Oncology Tube)
Source: Oncology Tube - November 5, 2013 Category: Cancer & Oncology Source Type: podcasts
Is nindetanib a new agent worthy of becoming a new treatment for advanced NSCLC?
http://cancerGRACE.org/...
Dr. Nate Pennell from Cleveland Clinic reviews the LUME Lung-1 trial presented by Reck at ASCO 2013, of Taxotere with or without nindetanib (BIBF-1120), an anti-angiogenic m...
Author: cancergrace
Added: 06/26/2013 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2013 Category: Cancer & Oncology Source Type: podcasts
Can a "heat shock protein inhibitor" in standard chemo improve outcomes in advanced NSCLC?
http://cancerGRACE.org/...
Drs. Mary Pinder, Nate Pennell, and Jack West discuss the results presented at ASCO 2013 of the GALAXY-1 trial of the HSP90 inhibitor ganetespib combined with Taxotere (doce...
Author: cancergrace
Added: 06/19/2013 (Source: Oncology Tube)
Source: Oncology Tube - June 19, 2013 Category: Cancer & Oncology Source Type: podcasts
GRACEcast-111_Lung-Cancer_ASCO 2012 LC Highlights: Dr. Socinski on TAILOR Trial in Advanced NSCLC
http://cancerGRACE.org/...
Dr. Mark Socinski from University of Pittsburgh summarizes and critiques the TAILOR trial of Taxotere (docetaxel) vs. Tarceva (erlotinib) in EGFR wild type advanced NSCLC.
Author: cancergrace
Added: 01/17/2013 (Source: Oncology Tube)
Source: Oncology Tube - January 17, 2013 Category: Cancer & Oncology Source Type: podcasts
